Liasny

Researchers are evaluating the outcomes of different extents of lymph node removal during radical prostatectomy in men with operable localized or locally advanced prostate cancer. This randomized controlled study aims to compare limited or no lymph node dissection versus extended lymph node dissection to determine the best surgical approach for patients with varying risk levels of prostate cancer. The study focuses on patients without metastatic cancer and those suitable for surgery based on overall health. Participants will undergo radical prostatectomy combined with either limited or extended lymph node dissection depending on their risk group. Patients with high or unfavorable intermediate risk prostate cancer will receive extended dissection, which includes removal of external iliac, obturator, internal iliac, and common iliac lymph nodes up to the ureter on both sides. Those with low or favorable intermediate risk will receive limited dissection involving only obturator and possibly external iliac nodes, or no lymph node removal in the lowest risk group. Throughout the study, researchers will monitor participants for metastasis-free survival over a five-year period from the time of enrollment. Assessments will include physical exams, imaging tests, and other evaluations to check for cancer spread and overall health. The study also includes safety monitoring and follow-up visits to track recovery and any complications related to the surgery or lymph node dissection techniques.

Researchers are evaluating an academic approach to chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory large B-cell lymphoma (LBCL). This study aims to assess the effectiveness and safety of academic CAR-T cell products, which may reduce costs and improve access compared to commercial therapies. The CAR-T cells target CD19-positive cancer cells and are produced using a lentiviral vector encoding an anti-CD19 CAR construct. The treatment involves an academic CAR-T cell product that includes an anti-CD19 monoclonal antibody fragment linked to signaling and safety components. This product is given to patients with relapsed or refractory LBCL who have previously received at least one line of anti-tumor therapy. The study is conducted at the NN Alexandrov National Cancer Centre of Belarus and focuses on real-world application of this therapy. Participants will be monitored for treatment response, including the objective response rate measured 30 days after infusion. Researchers will also assess safety and any side effects related to the therapy. The study includes adults aged 18 to 80 years with confirmed CD19 expression in tumor tissue. Laboratory tests and clinical evaluations will support ongoing assessment during the study.